Cite
A phase 1 dose-escalation study of NEO-102 in patients with refractory colon and pancreatic cancer.
MLA
Beg, Muhammad, et al. “A Phase 1 Dose-Escalation Study of NEO-102 in Patients with Refractory Colon and Pancreatic Cancer.” Cancer Chemotherapy & Pharmacology, vol. 78, no. 3, Sept. 2016, pp. 577–84. EBSCOhost, https://doi.org/10.1007/s00280-016-3108-5.
APA
Beg, M., Azad, N., Patel, S., Torrealba, J., Mavroukakis, S., Beatson, M., Wang, X., Arlen, P., Morse, M., Beg, M. S., Azad, N. S., Patel, S. P., Beatson, M. A., Wang, X. P., Arlen, P. M., & Morse, M. A. (2016). A phase 1 dose-escalation study of NEO-102 in patients with refractory colon and pancreatic cancer. Cancer Chemotherapy & Pharmacology, 78(3), 577–584. https://doi.org/10.1007/s00280-016-3108-5
Chicago
Beg, Muhammad, Nilofer Azad, Sandip Patel, Jose Torrealba, Sharon Mavroukakis, Melony Beatson, Xue Wang, et al. 2016. “A Phase 1 Dose-Escalation Study of NEO-102 in Patients with Refractory Colon and Pancreatic Cancer.” Cancer Chemotherapy & Pharmacology 78 (3): 577–84. doi:10.1007/s00280-016-3108-5.